Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | p28 |
Synonyms | |
Therapy Description |
p28 is a peptide derived from the protein azurin, which enters the nucleus, binds to Tp53, and prevents Tp53 degradation, potentially leading to increased cell-cycle arrest and decreased tumor growth (PMID: 23449360). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
p28 | p28 is a peptide derived from the protein azurin, which enters the nucleus, binds to Tp53, and prevents Tp53 degradation, potentially leading to increased cell-cycle arrest and decreased tumor growth (PMID: 23449360). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 positive | Advanced Solid Tumor | predicted - sensitive | p28 | Phase I | Actionable | In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360). | 23449360 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|